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Abstract
Background: Recurrent chest pain is common in patients with and without coronary artery disease. The prevalence
and burden of these symptoms on healthcare is unknown.
Objectives: To compare chest pain return visits (recidivism) in patients with unexplained chest pain (UCP) against
reference group of patients with coronary artery disease (CAD) and estimate the annual cost of recurrent chest pain.
Methods: In a retrospective cohort study, a Veteran Affairs (VA) administrative and clinical database of Veterans who
were deployed to or served in support of the wars in Iraq or Afghanistan was queried for first disease specific ICD-9
code to form two cohorts (UCP or CAD). Patients were followed between 09/2001-09/2010 for the first and cumulative
return visits for UCP or cardiac pain (ACS or angina) to clinic, emergency department or admission; or for all-cause
death. Time to return was analyzed using Cox regression and negative binomial models and adjusted for age, gender,
race, marital status, and risk factors (hypertension, hyperlipidemia, diabetes, smoking and obesity). Direct total costs
included inpatient, outpatient and fee basis (non-VA) costs.
Results: Of 749,036 patients, 20,521 had UCP and 5303 had CAD. UCP patients were young and had a lower burden of
risk factors than CAD cohort (p < .01). Yet, these patients were likely to return earlier with any chest pain (adjusted
Hazard Ratio [aHR] = 1.76; 95 % CI 1.65-1.88); or unexplained chest pain than CAD patients (aHR: 1.89; 95 % CI 1.77-2.01).
UCP patients were also likely to return more frequently for any chest pain (aRate Ratio = 1.54; 95 % CI 1.43-1.64) or UCP
than CAD patients (aRR =2.63; 95 % CI 2.43-2.87). Per 100 patients, the 1-year cumulative returns were 37 visits for
reference group and 45 visits for UCP cohort. The annual costs for chest pain averaged $69,009 for CAD and
$57,336 for UCP patients (log geometric mean ratio=1.25; 95 % CI 1.18-1.32).
Conclusion: Chest pain recidivism is common and costly even in patients without known CAD. We need
evidence-based guidelines for these patients to minimize returns.
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Background
Chest pain is one of the most common conditions seen in
the primary care setting. In fact, 20-40 % of the population
experiences some chest pain over their lifetime. In the
United States, over eight million patients with chest pain
are evaluated in the outpatient setting each year, posing a
significant health burden [1]. Primary care physicians across
the world face the challenge of distinguishing life threaten-
ing cardiac causes of chest pain from non-cardiac etiologies
and of doing this in a timely and efficient fashion. The stand-
ard of care for chest pain patients is to first rule out acute cor-
onary syndrome (ACS) [2, 3]. However, musculoskeletal
causes of chest pain are the most common cause in primary
care followed by gastrointestinal, pulmonary, psychological
(depression or PTSD) or microvascular disease–all common
in young patients [4–7]. Several diagnostic algorithms have
been proposed to help the clinician reach a diagnosis in these
cases [8]. And yet, a good proportion of cases remain ‘non-
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specific’ or ‘unexplained chest pain’ (UCP). This is evident
from an upward trend in unexplained chest pain admissions
nationwide despite declining ACS trends [9, 10]. In contrast
to ACS patients, UCP is more common in young patients and
in women corroborating their low-risk pre-test probability for
CAD [9, 11, 12]. Deciding the appropriate level of response for
such patients is both difficult task and variable, often leading
to both over- and under-triage in primary care [13]. While the
annual cost burden of heart disease has been estimated at
$312 billion, similar costs of unexplained chest pain that repre-
sentmajority of primary care visits remain unknown [14, 15].
We evaluated these questions in the Veteran Affairs (VA)
health care system using the Women Veteran Cohort Study
(WVCS), with its detailed electronic health records provid-
ing longitudinal data of service utilization and costs of Vet-
erans of Operation Enduring Freedom (OEF), Operation
Iraqi Freedom (OIF) and Operation New Dawn (OND)
[16]. Prior reports show that chest pain is common among
Veterans [17]. We chose this cohort because it primarily
included young patients allowing us to estimate the bur-
den of UCP in low-risk patients, and the single insurance
with a well-integrated electronic medical records system
allowed us longitudinal follow-ups. VA facilities located
throughout the US allow Veterans to continue VA care
despite relocation, thus allowing a prospective evaluation
of the full burden and cost of unexplained chest pain. The
main aim of our study was to document the burden of
chest pain recidivism in young patients without CAD.
Our hypothesis was the chest pain recidivism would be
less in the low-risk UCP group compared to a reference
group of patients with known CAD. The secondary out-
come was calculating the annual costs associated with un-
explained chest pain.
Methods
Study population and data sources
The Defense Manpower Data Center provided the VA
OEF/OIF/OND roster for personnel discharged from the
US military from 09/12/2001 to 09/30/2010 and enrolled
for VA care. Data on their services and costs were linked
to the VA administrative and clinical encounters to the
VA National Patient Care Database, Decision Support
Systems (DSS), National Data extracts and the VA
Corporate Data Warehouse. Detailed information on
services paid for by VA but provided by non-VA facilities
or contract providers, including inpatient, outpatient
and pharmacy care was obtained from the DSS Fee Basis
files. The Human Investigation Committees at West
Haven VA Medical Center and Yale University School of
Medicine approved this study.
Inclusion criteria and variable definitions
For diagnostic data, the International Classification of
Disease, 9th Revision (ICD-9) was used and medical
conditions were included if the specific code was noted
at least once for an inpatient stay, observation or ED
stay or at least twice for an outpatient visit. This
methodology for the use of ICD-9 codes in VA database
has been validated elsewhere [18].
For co-morbidities, we used previously validated diag-
nostic algorithms for diabetes, hypertension, dyslipid-
emia, obesity, and CAD [19]. We defined dyslipidemia
if patient had ICD-9 code for dyslipidemia or was on
statins for a year. We included active smokers [20]. Body
mass index was calculated using weight and height
averaged over a 1-year period.
Study cohort was defined based on the first diagnosis
after entry into the VA system (end of last deployment).
Those with an encounter listed as ICD-9 code ‘786.50’
entered the unexplained chest pain cohort and those
with CAD codes (see Additional file 1) formed known
CAD cohort. There were 151 (0.007 %) patients in the
first cohort that converted to CAD during follow up and
we included only their follow-up to CAD conversion in
the analysis.
Outcomes and follow-up
Outcomes included any return visit to the VA or non-
VA (fee basis) for either unexplained chest pain or
cardiac chest pain (myocardial infarction, stable or un-
stable angina), or death. Patients were followed until
study outcome or exit from the cohort during a ten-
year study period. ICD-9 codes included were chest
pain (786.50), CAD (414.x and 429.x), acute myocardial
infarction (410.x), unstable angina (411.x) or angina
(413.x) as primary or secondary diagnosis. Time to re-
turn visit as well as the cumulative number of chest
pain visits were recorded.
Total health care costs were computed by summing
all costs across inpatient, outpatient and pharmacy
services after identification of cohort. Costs included
both costs of services delivered in VA facilities as well
as costs of services delivered by non-VA care(fee-basis)
providers. Finally each of these measures were linked to
the cardiac ICD-9 codes outlined above to determine
the cost of care for both groups of patients.
Analysis
Continuous variables were expressed as mean +/−
standard deviation and compared by unpaired Student’s t
test. Nominal or dichotomous variables were expressed as
proportions and compared by chi-square test. Kaplan
Meier curves were estimated to show those without a
return visit by cohort and gender for (a) any chest pain
(i.e., unexplained chest pain or cardiac chest pain) and b)
unexplained chest pain only. Time to return visit and
incident rate for death was compared using Cox regres-
sion with adjustment for age, gender, race, marital status,
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education, hypertension, dyslipidemia, smoking, diabetes,
obesity (defined as BMI ≥30), cohort and interaction
terms with gender.
Cumulative incident return rates were calculated per
patient from the point of entry to last follow up. Crude
incident rates were calculated by dividing the total num-
ber of return visits for chest pain by the total number of
patients in each cohort for the duration of observation
for each patient. All eligible index visits for chest pain
were used as the unit of analysis. This way we captured
multiple visits for the same patients. All rates were
expressed as the total per 10000 visits. Rate ratios and
confidence level for all rates were calculated using a
generalized linear model with a negative binomial distri-
bution and an offset of the log years of follow-up given
the variable observation period for each patient. Separate
adjusted models were constructed using the socio-
demographic and cardiac risk factors listed above. The
mean number of return visits per subject was calculated
using a nonparametric estimator [21].
Total costs were compared across the two cohorts using
geometric means and Mann-U-Whitney tests because of
extreme right skewness. A generalized linear model with a
log link function was developed to identify and adjust for
differences in demographic, cardiac risk factors and year of
entry (to account for inflation). Because pharmacy costs are
not coded by diagnosis, all prescription use was compared
for the two cohorts.
All analysis was performed using SAS v.9.0. P-values
of <0.05 were considered statistically significant.
Results
The study cohort followed 749,036 patients prospectively
over ten years of which 2592 (2.9 %) females and 18,010
(2.7 %) males reported chest pain. After entering the VA
system, 20,521 patients entered the unexplained chest
pain (UCP) cohort and 5303 patients constituted the
CAD (reference) cohort based on the first diagnosis and
were analyzed. As expected, our cohort was young with
median age 34 years (IQR 24, 42),11 % female and 66 %
white. Overall cardiac risk factor profile was as follows:
39 % had hypertension, 12 % were diabetic, 45 % had
dyslipidemia, 38 % smoked and 31 % were obese. Known
CAD patients were more likely to be older, male, white,
married and had a higher rate of co-morbidities
(see Table 1).
Primary outcome
Patients were followed over an average of 2.02 years for
the following:
a) First return visit for chest pain
The 1-month and 1-year probability of a return visit for
any chest pain was 14.2 % and 26.6 % respectively in the
unexplained chest pain cohort versus 8 % and 18.4 % in
Table 1 Baseline demographic characteristics of patients by gender and cohort
Characteristic Coronary Artery Disease Unexplained Chest Pain Difference Between Cohorts
(n = 5303) (n = 20521)
21 % 79 %
Total Female Male Total Female Male P value
CAD 6 % 94 % UCP 13 % 87 %
Median Age in years (IQR) 42 (34,49) 38 (26,44) 42 (34,49) 31 (23,40) 29 (23,39) 31 (23,40) <.001
Race
White 58 % 41 % 59 % 55 % 42 % 57 % <.001
Black 19 % 38 % 18 % 21 % 36 % 19 %
Hispanic 9 % 6 % 9 % 12 % 9 % 13 %
Others 14 % 15 % 14 % 12 % 13 % 11 %
Married 69 % 41 % 71 % 51 % 35 % 54 % <.001
Educated (High School or higher) 99 % 99 % 99 % 99 % 99 % 99 % 0.02*
Cardiac Risk Factors
Hypertension 50 % 31 % 51 % 29 % 21 % 30 % <.001
Diabetes 14 % 7 % 14 % 5 % 4 % 6 % <.001
Hyperlipidemia 57 % 34 % 58 % 33 % 22 % 35 % <.001
Smoking 37 % 29 % 38 % 39 % 29 % 40 % 0.01
Obesity 33 % 30 % 33 % 28 % 25 % 28 % <.001
Note: Table percentage are column percentage; *percentage are rounded off to the nearest decimal; the p is significant at > .05 level using Chi-sq Test
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the CAD cohort (Crude HR = 1.39, 95 % CI 1.31-1.47)
(Fig. 1a). Adjusted Cox regression showed UCP patients
were 76 % more likely to return earlier with chest pain
as compared to CAD patients (Adjusted HR = 1.76; 95 %
CI 1.65-1.88).
The 1-month and 1-year probability of a return visit
for unexplained chest pain alone was higher (13.4 % and
25.3 %) in the UCP cohort than the reference group (4 %
and 10.8 %) (Crude HR = 1.49; 95 % CI 1.41-1.59)
(Fig. 1b). After adjustment, UCP patients were 89 %
more likely to return earlier for unexplained chest pain
as compared to CAD patients (Adjusted HR: 1.89; 95 %
CI 1.77-2.01).
b) Cumulative returns for chest pain
Negative binomial regression comparing cumulative
return visits for chest pain for the duration of follow
up revealed that patients with UCP were 58 % more
likely to return for any chest pain (Rate Ratio = 1.58;
95 % CI 1.47-1.71) and 2.6 times more likely to re-
turn with unexplained chest pain than the reference
group (Rate Ratio = 2.63; 95 % CI 2.43-2.87) (Table 2).
Two hundred and nine (0.01 %) patients died in
UCP group compared to 106 (0.02 %) CAD patients
(HR = 0.61; 95 % CI 0.45-0.83).
Figure 2 shows the cumulative return visits for any
chest pain by cohort. The 30-day mean return visits
Fig. 1 Kaplan-Meier Curves for Time to First return for Chest Pain By Gender and Cohort
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were 11 visits per 100 CAD patients and 17 visits per
100 UCP patients. The rates were consistently 12-15 %
higher in the UCP cohort compared to the reference
group at 3 months, 6 months and at 1 year from the
index visit (Fig. 2).
The adjusted time to first return or cumulative rates
of return visits did not differ by gender (Figs. 1 and 2).
Secondary outcome
Cost comparison
Figure 3 shows mean and median costs for UCP patients
that were comparable to those of patients in the CAD
cohort. Mean costs were averaged across all follow up
years including those with zero costs. The mean per pa-
tient total cost was $11,804 higher in the CAD cohort as
compared to the UCP cohort. Given highly skewed data,
we compared the cohorts using geometric means as well
as winsorized means at 5 % and 10 % cut off values and
did not find a difference (results not shown).
After adjustment for socio-demographics and car-
diac risk factors using a generalized linear model with
a log link function, CAD patients incurred 25 % higher
costs than patients with unexplained chest pain (Log
geometric mean ratio=1.25; 95 % CI 1.18-1.32). Costs were
heavily skewed, as the median costs as well as distribution
of costs were similar between both groups (Fig. 3). Figure 3
shows the percent distribution of total costs across care
setting for the two cohorts. Costs for procedures were
16.89 % of the total costs for UCP cohort and 16.18 % for
the CAD cohort, while total pharmacy costs were 10.13 %
of the total costs for the UCP cohort and 13.89 % for the
CAD cohort.
Discussion
To our knowledge, this is the first US study that has
quantified the recidivism and cost burden of unex-
plained chest pain in young patients. In a geographically
representative national database, we found that young
Veterans without coronary disease had recurrent chest
pain earlier and 1.5 times more frequently than the
reference group with known CAD. Studies from the UK
and Norway have shown similar high burden of unex-
plained chest pain [13, 22]. We also report the cost
burden of unexplained chest pain in the VA system. Al-
though the adjusted average cost of chest pain visits was
25 % higher with CAD, median costs and distribution of
Fig. 2 Annual Cumulative Rates of Return for Unexplained Chest Pain by Cohort
Table 2 Incidence rates for return visits by cohort
Incidence Rate
(per 10,000 person-years)
Unadjusted Rate Ratio/Hazard Ratio
(with 95 % confidence intervals)
P value Adjusted Rate Ratio/Hazard Ratioa
(with 95 % confidence intervals)
P value
Cohort Unexplained CP Known CAD
Any Return for CP 8.2 7.1 1.25 (1.16-1.35)b <0.0001* 1.54 (1.43-1.66)b <0.0001*
Unexplained CP Return 7.5 3.9 2..23 (2.05-2.40)b <0.0001* 2.63 (2.43-2.87)b <0.0001*
Death 0.1 0.2 0.51 (0.39-0.68)b,c 0.0001* 0.61 (0.45-0.83)b,c 0.0018*
Notes: Rates area expressed in 10,000 person years; table percentages are column percentages; *the p is significant at > .05 level
aadjusted for age in decades, white race, higher education, marital status, hypertension, diabetes, hyperlipidemia, smoking and obesity; there was no interaction
found between gender and cohort
bratio of rates of return visits in Unexplained chest pain cohort/CAD cohort
cCox regression model used to calculate hazard rates
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inpatient, outpatient and non-VA care (fee basis) costs
of chest pain were comparable in both cohorts. With
the Affordable Care Act of 2010 linking readmissions to
hospital reimbursement and value-based purchasing, we
believe this information is of value to hospitals and
clinicians.
Our study adds several interesting findings to the
existing literature. First, we found prevalence of unex-
plained chest pain to be high in young Veterans without
coronary artery disease. This is consistent with reports
from civilian population that show chest pain syndromes
are more common in young patients [4, 22–25].
Second, we found chest pain recidivism to be high in
young Veterans. The 30-day return rate was twice in our
cohort compared to civilian reports [26]. Chest wall
syndromes are often associated with high recurrence
rates [27]. Patients with unexplained chest pain often
view their condition as significantly less controllable and
less understandable than those with pain of cardiac
origin [28]. The CAD conversion rate was very low in
our cohort suggesting non-cardiac cause of recurrent
chest pain. Our prior work documented high rates of
depression (30 %) and PTSD (17 %) as well as musculo-
skeletal conditions in the WVCS cohort that could con-
tribute towards recurrent non-cardiac chest pain [16].
Depression and anxiety has been linked with increased
rates of recurrent chest pain, either through increased
somatization or by reducing release of nitric oxide and
potential decrease in endothelial reactivity [29, 30]. It is
also possible that some of these patients returned due to
uncertainty of diagnosis. Prior reports have shown that
increased awareness of the possibly dangerous ramifica-
tions of chest pain may drive patients back to the
hospital for recurrent symptoms despite an initial car-
diac work up [31]. In this study, we have quantified the
rates of recidivism. We did not collect data on diagnostic
work-ups on these patients and it is possible that due to
the lower pretest probability these young Veterans did
not get a comprehensive ‘rule out ACS’ evaluation
prompting early returns. However such approach would
not entirely explain the high annual costs incurred by
this cohort or the high cumulative rates of return visits.
Finally, the cost implications of recurrent chest pain
are important. Prior reports demonstrate escalating costs
of unexplained chest pain admissions over the past
decade [9]. In this study, we report additional outpatient
costs of UCP in comparison with CAD costs in the VA
system. We found the cost of recurrent chest pain to be
high despite low pre-test probability of CAD in young
Veterans. Annual inpatient cost averaged $3498 per
patient for chest pain and $4327 for CAD. This was
similar to the national average cost of unexplained chest
pain ($4014) as paid by Medicare [32]. The primary cost
driver in the VA was outpatient visits (clinics, emergency
departments and urgent care), where 80 % of chest pain
patients are ruled out for ischemia. We recognize the
financing mechanisms that are unique to the VA, how-
ever these are important hypothesis generating results
that should be investigated in the civilian population. If
corroborated in the six million annual civilian chest pain
Fig. 3 Unadjusted Direct Costs of Unexplained Chest Pain
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ED visits, at an annual average total cost of $57,336 for
unexplained chest pain per patient, our study projects
an annual national health burden of up to $344 billion
due to recurrent chest pain. This would be in addition
to the $312 billion cost of CAD based on prior reports
of admission costs [33].
For practicing clinicians, we feel that the large popu-
lation base investigated in our study, together with
evidence from other studies, highlights the need to
recognize unexplained chest pain as a heterogeneous
syndrome and the relative importance of continuing
work up for a definitive diagnosis. Our present system
evaluates acute chest pain primarily through an ‘ACS
lens’–understandable given that missed myocardial
infarction is associated with high mortality [34]. How-
ever the CAD conversion rates in our young cohort
remained low (0.007 % UCP patients converted to
CAD) corroborating their low-risk for CAD. This
coupled with low mortality in this group underscores
the need to look beyond tier one outcome (survival) in
young patients with recurrent chest pain. Some authors
have proposed diagnostic algorithms to facilitate work
ups and even cost saving strategies such as initiation of
high dose gastric acid suppressive therapy after ruling
out cardiac causes [8, 35]. We need more research to
better quantify these causes and develop evidence-
based guidelines for managing persistent chest pain
that are value-based, patient centered and integrated
towards a ‘rule in’ strategy [36]. Documenting the
prevalence and cost of this condition is the first step in
this direction.
Limitations
Our study has several limitations. First, we used an
administrative database that relied on ICD-9 codes and
did not capture the granularity of diagnostic work ups.
The findings are therefore subject to the accuracy and
subjectivity of ICD code documentation as well as pre-
sumed adequacy of patient work ups. Further work is
needed to determine the definitive diagnoses eventually
given to these patients. Second, the costs cannot be
generalized to all Veterans because the data were limited
to those seeking VA care. However our cohort was
young (75 % less than 50 years) and unlikely to have
alternate insurance such as Medicare. Our results may
then actually underestimate the rates of return visits.
Third, it is possible that some patients were redeployed
during the follow up period, however symptomatic
patients with chest pain are unlikely to be deployed.
Fourth, it is possible that coding errors occurred.
However our findings from previous studies show
good reliability [18]. Fourth, this VA cohort is young
and unique that could affect the generalizability of our
findings. However UCP is also common in younger
cohorts in patients largely free of CAD as reported by
Fagring et al. from a population-based study [12]. It is
also interesting to see that despite lower pretest
probability of CAD, this young cohort incurred high
costs of care. Fifth, we only used all cause-mortality in
our outcomes and did not compare the reason of
death. However, given the low mortality rates in this
cohort, it may not influence the interpretation of our
findings. Finally our study was based on physician
diagnosis rather than patient-reports, and therefore
likely represents and underestimate of the burden of
disease [7].
Conclusion
Unexplained chest pain is common and a frequent cause
of recidivism in young Veterans without known CAD.
With a projected annual cost of over $300 billion, unex-
plained chest pain represents an unidentified source of
major cost to the health system and warrants further
investigation.
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